Creon: Phase III data

Data from a double-blind, international Phase III trial in 52 patients showed that Creon met the primary endpoint of significantly improving fat absorption as measured by the mean coefficient of fat absorption (CFA) vs. placebo (32.1% vs. 8.8%, p<0.0001). On secondary endpoints, Creon significantly improved stool characteristics, flatulence and stool consistency vs. placebo. Creon was well tolerated with an adverse event profile similar to that of placebo. Data were presented at the American College of Gastroenterology meeting in San Diego. ...